Puretech Health Plc ADR (PRTC)

Apr 30, 2025, 7:56 PM EDT - 3 hours ago

PureTech Health plc (PRTC) Q4 2024 Earnings Call Transcript

Apr 30, 2025, 2:00 AM EDT - 21 hours ago

PureTech Announces Annual Results for Year Ended December 31, 2024

Apr 23, 2025, 2:00 AM EDT - 7 days ago

PureTech Health: Notice of Results

Apr 9, 2025, 2:00 AM EDT - 21 days ago

PureTech Appoints Peel Hunt as Joint UK Corporate Broker

Apr 7, 2025, 12:16 PM EDT - 23 days ago

PureTech Health plc Statement Regarding Press Speculation

Mar 11, 2025, 7:05 AM EDT - 7 weeks ago

PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

Feb 12, 2025, 7:05 AM EST - 2 months ago

PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform

Jan 27, 2025, 2:00 AM EST - 3 months ago

PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine

Jan 9, 2025, 7:00 AM EST - 3 months ago

PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)

Jan 6, 2025, 2:00 AM EST - 4 months ago

PureTech Appoints UBS as UK Corporate Broker

Dec 16, 2024, 2:00 AM EST - 4 months ago

PureTech's Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial

Dec 11, 2024, 7:05 AM EST - 5 months ago

PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024

Dec 9, 2024, 2:00 AM EST - 5 months ago

PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting

Nov 20, 2024, 7:05 AM EST - 5 months ago

PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors

Oct 1, 2024, 7:00 AM EDT - 7 months ago

PureTech to Present at CHEST 2024 Annual Meeting

Aug 28, 2024, 2:26 PM EDT - 8 months ago

PureTech Health plc (PRTC) Q2 2024 Earnings Call Transcript

Aug 28, 2024, 2:01 AM EDT - 8 months ago

PureTech Health plc – Half-Year Report

Aug 21, 2024, 2:00 AM EDT - 9 months ago

PureTech Health: Notice of Half-Yearly Results

Jun 24, 2024, 2:00 AM EDT - 11 months ago

PureTech Health: Results of the Tender Offer

Jun 20, 2024, 2:00 AM EDT - 11 months ago

PureTech Announces Change of Board Role

Jun 18, 2024, 7:05 AM EDT - 11 months ago

PureTech Founded Entity Seaport Therapeutics Appoints Seasoned Executives to Management Team

Jun 13, 2024, 1:15 PM EDT - 11 months ago

PureTech Health: Results of Annual General Meeting

Jun 6, 2024, 12:38 PM EDT - 11 months ago

PureTech Health: Result of General Meeting

May 29, 2024, 8:09 AM EDT - 1 year ago

PureTech Founded Entity Akili Interactive and Virtual Therapeutics Announce Entering Into Definitive Merger Agreement to Establish Leading Digital Health Company

AKLI

May 23, 2024, 7:00 AM EDT - 1 year ago

PureTech to Present at the Jefferies Global Healthcare Conference

May 21, 2024, 7:05 AM EDT - 1 year ago

PureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection

May 20, 2024, 2:00 AM EDT - 1 year ago

PureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary Share

May 9, 2024, 7:05 AM EDT - 1 year ago

PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting

May 7, 2024, 7:05 AM EDT - 1 year ago

PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments

Apr 25, 2024, 11:56 PM EDT - 1 year ago

PureTech Health plc (PRTC) Q4 2023 Earnings Call Transcript

Apr 25, 2024, 5:22 AM EDT - 1 year ago

PureTech Announces Annual Results for Year Ended December 31, 2023

Apr 16, 2024, 7:00 AM EDT - 1 year ago

PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis

Apr 11, 2024, 7:00 AM EDT - 1 year ago

PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers

Apr 9, 2024, 2:00 AM EDT - 1 year ago

PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions

Mar 23, 2024, 7:52 AM EDT - 1 year ago

PureTech Health: Repeat What Works

Mar 18, 2024, 9:52 AM EDT - 1 year ago

Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion

BMY

Feb 27, 2024, 7:00 AM EST - 1 year ago

PureTech to Present at Two Upcoming Investor Conferences

Feb 27, 2024, 2:00 AM EST - 1 year ago

PureTech Founded Entity Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx ® for Pediatric ADHD Patients in Japan

AKLI

Nov 29, 2023, 10:17 AM EST - 1 year ago

PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia

Aug 29, 2023, 2:00 AM EDT - 1 year ago

PureTech Health plc – Half-Year Report

Apr 28, 2023, 2:00 AM EDT - 2 years ago

PureTech Announces Annual Results for Year Ended December 31, 2022

Mar 23, 2023, 3:00 AM EDT - 2 years ago

PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million

RPRX

Feb 27, 2023, 9:05 AM EST - 2 years ago

PureTech Founded Entity Sonde Health and Massachusetts General Hospital Selected for National Institute on Aging Study to Examine Use of Voice in Remote Detection and Monitoring of Mild Cognitive Impairment Including Frontotemporal Disorders (FTD)

Feb 1, 2023, 7:00 AM EST - 2 years ago

PureTech to Present at the SVB Securities Global Biopharma Conference

Jan 26, 2023, 7:00 AM EST - 2 years ago

Vedanta Biosciences to Present at Upcoming Investor Conferences

Dec 22, 2022, 2:00 AM EST - 2 years ago

PureTech Provides End of Year Report on Key Progress

Dec 19, 2022, 7:00 AM EST - 2 years ago

PureTech's LYT-300 (Oral Allopregnanolone) Demonstrates Oral Bioavailability, Tolerability and GABAA Receptor Target Engagement in Healthy Volunteers

Dec 13, 2022, 7:00 AM EST - 2 years ago

PureTech to Present at 41st Annual J.P. Morgan Healthcare Conference

Dec 12, 2022, 9:00 AM EST - 2 years ago

PureTech Presents Data for LYT-200 Targeting Galectin-9 in Preclinical Leukemia Cancer Models at the 64th American Society of Hematology (ASH) Annual Meeting

Dec 9, 2022, 7:00 AM EST - 2 years ago

PureTech Founded Entity Sonde Health Raises $19.25 Million Series B for Voice-Based Health Monitoring